- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02962674
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
ProstaCare Water Electrolysis System for the Treatment of Benign Prostatic Hyperplasia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tauranga, New Zealand, 3112
- Urology Bay of Plenty (BOP)
-
-
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 119074
- National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- 45 years of age or older with a diagnosis of BPH,
- International Prostate Symptom Score (IPSS) of 12 or greater,
- Prostate volume between 25 cm3 and 55 cm3,
- Uroflow with peak flow rate (Qmax) no greater than 13 ml/sec with a corresponding voided volume of at least 100 ml and a post void residual (PVR) of 250 ml or less.
- Prostate length, width and height must be at least 3.2 cm, 3.5 cm and 2.5 cm, respectively
Key Exclusion Criteria:
- Obstruction due to an enlarged middle lobe, central gland or significant transverse asymmetry,
- Subjects on 5 alpha reductase inhibitors (5-ARI) (inclusion only if washed out prior to treatment),
- Subjects on alpha blockers (inclusion only if washed-out before treatment),
- Active urinary tract infection at time of treatment,
- Interest in maintaining fertility,
- Past history of urologic surgery or minimally invasive treatment for BPH,
- History of or current medical conditions contraindicating elective urological procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean International Prostate Symptom Score (IPSS) at 3 Months Follow-up Visit
Time Frame: 3 months after treatment
|
The primary effectiveness objective was to demonstrate that mean IPSS improvement (Δ IPSS) following treatment with the prostaFix System exceeded 6.5 points with 95% confidence 3 months after treatment. The International Prostate Symptom Score (IPSS) is a validated questionnaire used to assess baseline and post treatment BPH symptoms. It is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the subject to choose one out of six answers indicating increasing severity of that particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic): Mild (symptom score less than or equal to 7), Moderate (symptom score range 8-19) and Severe (symptom score range 20-35). Improvement in BPH symptoms is seen as a decrease in IPSS. |
3 months after treatment
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: 3 months after treatment
|
The primary safety objective of this study was to estimate the proportion of subjects affected by serious adverse events (SAEs) associated with the use of the device.
This objective was addressed through recording all adverse events (AEs) observed or reported during the course of the study.
|
3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in QOL From Baseline
Time Frame: Baseline and 3 months after treatment
|
Question eight of the IPSS questionnaire refers to the subject's perceived quality of life (QOL).
The International Scientific Committee (SCI), under the patronage of the World Health Organization (WHO) and the International Union Against Cancer (UICC), recommends the use of only a single question to assess the quality of life.
The answers to this question range from "delighted" to "terrible" or 0 to 6.
|
Baseline and 3 months after treatment
|
Mean Change in Peak Flow Rate (Qmax) From Baseline
Time Frame: Baseline and 3 months after treatment
|
Uroflowmetry measures the flow of urine.
It tracks how fast urine flows (peak flow rate - Qmax), how much flows out, and how long it takes.
It's a diagnostic test to assess how well the urinary tract functions.
Uroflowmetry is used in BPH subjects to help the doctors determine how well the subject's urinary tract is doing and the severity of obstruction caused by the prostate.
The higher the Qmax is, the less obstructed the urethra.
|
Baseline and 3 months after treatment
|
Mean Change in Post Void Residual (PVR) From Baseline
Time Frame: Baseline and 3 months after treatment
|
The Post Void Residual (PVR) is an indicator of urine remaining in the bladder after voiding.
A healthy bladder should be fairly empty following urination.
A volume < 50 mL is normal; < 100 mL is usually acceptable in patients > 65 years old.
The higher the PVR, the more urine is left in the bladder and this can be seen as a sign of increased obstruction of the urethra.
|
Baseline and 3 months after treatment
|
Mean Change in MSHQ-EjD Score From Baseline
Time Frame: Baseline and 3 months after treatment
|
The MSHQ-EjD Short Form (Male Sexual Health Questionnaire - Ejaculatory Disfunction) is composed of three questions that rate ejaculatory function in men. A fourth question measures the MSHQ-EjD Bother, this asks the subject if he is bothered by his level of ejaculatory function. MSHQ-EjD total score ranges from 1 to 15 with a higher score indicating better sexual functioning. MSHQ-EjD bother score ranges from 0 to 5 with a higher score indicating greater bother. An increase in the MSHQ-EjD Total Score indicates better ejaculation and a decrease in the MSHQ-EjD Bother Score means that the subject is less bothered by his ejaculatory function. Due to the sensitive nature of the questions, this questionnaire is voluntary and not all subjects completed it at baseline. Some subjects completed at baseline but decided not to complete at certain follow-up visits which explains the different number of participants during various analysis time frames. |
Baseline and 3 months after treatment
|
Change in IIEF Score From Baseline
Time Frame: Baseline and 3 months after treatment
|
The IIEF (International Index of Erectile Function) provides a broad measure of sexual function; an increase in score indicates an improvement in sexual function.
This questionnaire consists of five questions that asks the subject of any erection problems that have impacted his sexual life over the past 4 weeks or since the last study visit, whichever is shorter.
IIEF total score ranges from 0 to 25 with a higher score indicating better sexual functioning and an increase in score indicates an improvement in sexual function.
Due to the sensitive nature of the questions, this questionnaire is voluntary and not all subjects completed it at baseline.
Some subjects completed at baseline but decided not to complete at certain follow-up visits which explains the different number of participants during various analysis time frames.
|
Baseline and 3 months after treatment
|
Mean Change in IPSS From Baseline
Time Frame: Baseline and 12 months from treatment
|
The International Prostate Symptom Score (IPSS) is a validated questionnaire used to assess baseline and post treatment BPH symptoms.
It is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life.
Each question concerning urinary symptoms allows the subject to choose one out of six answers indicating increasing severity of that particular symptom.
The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic): Mild (symptom score less than or equal to 7), Moderate (symptom score range 8-19) and Severe (symptom score range 20-35).
Improvement in BPH symptoms is seen as a decrease in IPSS.
|
Baseline and 12 months from treatment
|
Mean Change in QOL From Baseline
Time Frame: Baseline and 12 months from treatment
|
Question eight of the IPSS questionnaire refers to the subject's perceived quality of life (QOL).
The International Scientific Committee (SCI), under the patronage of the World Health Organization (WHO) and the International Union Against Cancer (UICC), recommends the use of only a single question to assess the quality of life.
The answers to this question range from "delighted" to "terrible" or 0 to 6.
|
Baseline and 12 months from treatment
|
Mean Change in Peak Flow Rate (Qmax) From Baseline
Time Frame: Baseline and 12 months from treatment
|
Uroflowmetry measures the flow of urine.
It tracks how fast urine flows (peak flow rate - Qmax), how much flows out, and how long it takes.
It's a diagnostic test to assess how well the urinary tract functions.
Uroflowmetry is used in BPH subjects to help the doctors determine how well the subject's urinary tract is doing and the severity of obstruction caused by the prostate.
The higher the Qmax is, the less obstructed the urethra.
|
Baseline and 12 months from treatment
|
Mean Change in Post Void Residual (PVR) From Baseline
Time Frame: Baseline and 12 months from treatment
|
The Post Void Residual (PVR) is an indicator of urine remaining in the bladder after voiding.
A healthy bladder should be fairly empty following urination.
A volume < 50 mL is normal; < 100 mL is usually acceptable in patients > 65 years old.
The higher the PVR, the more urine is left in the bladder and this can be seen as a sign of increased obstruction of the urethra.
|
Baseline and 12 months from treatment
|
Mean Change in MSHQ-EjD From Baseline
Time Frame: Baseline and 12 months from treatment
|
The MSHQ-EjD Short Form (Male Sexual Health Questionnaire - Ejaculatory Disfunction) is composed of three questions that rate ejaculatory function in men. A fourth question measures the MSHQ-EjD Bother, this asks the subject if he is bothered by his level of ejaculatory function. MSHQ-EjD total score ranges from 1 to 15 with a higher score indicating better sexual functioning. MSHQ-EjD bother score ranges from 0 to 5 with a higher score indicating greater bother. An increase in the MSHQ-EjD Total Score indicates better ejaculation and a decrease in the MSHQ-EjD Bother Score means that the subject is less bothered by his ejaculatory function. Due to the sensitive nature of the questions, this questionnaire is voluntary and not all subjects completed it at baseline. Some subjects completed at baseline but decided not to complete at certain follow-up visits which explains the different number of participants during various analysis time frames. |
Baseline and 12 months from treatment
|
Mean Change in IIEF From Baseline
Time Frame: Baseline and 12 months from treatment
|
The IIEF (International Index of Erectile Function) provides a broad measure of sexual function; an increase in score indicates an improvement in sexual function.
This questionnaire consists of five questions that asks the subject of any erection problems that have impacted his sexual life over the past 4 weeks or since the last study visit, whichever is shorter.
IIEF total score ranges from 0 to 25 with a higher score indicating better sexual functioning and an increase in score indicates an improvement in sexual function.
Due to the sensitive nature of the questions, this questionnaire is voluntary and not all subjects completed it at baseline.
Some subjects completed at baseline but decided not to complete at certain follow-up visits which explains the different number of participants during various analysis time frames.
|
Baseline and 12 months from treatment
|
MRI Necrosis Volume
Time Frame: 3 months after treatment
|
The prostaFix System uses pH shifts induced by water electrolysis to induce necrosis in the hyperplastic prostate tissue.
The induced necrosis within the borders of the prostate result in a pressure reduction and thereby relieve the symptoms of BPH.
This necrosis that resulted from the procedure eventually heals and necrosis volume should reduce overtime.
Per protocol, only the first 10-15 subjects would have MRI studies at done to assess subject safety and treatment effect.
then MRI was optional.
A total of 14 subjects actually had an MRI and the results are reported for those subjects.
|
3 months after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henry Ho Sun Sien, MD, Singapore General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP# PC 1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on prostaFix System
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms
-
University of British ColumbiaNot yet recruitingPersistent Developmental Stutter | Childhood-Onset Fluency Disorder (Stuttering)
-
National Institute of Neurological Disorders and...Recruiting